Report overview
Second-generation antipsychotics are serotonin-dopamine antagonists and are also known as atypical antipsychotics.
This report contains market size and forecasts of Long-Acting Schizophrenia Drug in Global, including the following market information:
Global Long-Acting Schizophrenia Drug Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Long-Acting Schizophrenia Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Oral Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Long-Acting Schizophrenia Drug include Johnson & Johnson, Teva, Eli Lilly, Bristol Myers Squibb, AstraZeneca, Sumitomo Dainippon Pharma, Allergan, Novartis and Cardinal Health, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Long-Acting Schizophrenia Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Long-Acting Schizophrenia Drug Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Long-Acting Schizophrenia Drug Market Segment Percentages, by Type, 2022 (%)
Oral
Injection
Global Long-Acting Schizophrenia Drug Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Long-Acting Schizophrenia Drug Market Segment Percentages, by Application, 2022 (%)
Hospital
Pharmacies
Other
Global Long-Acting Schizophrenia Drug Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Long-Acting Schizophrenia Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Long-Acting Schizophrenia Drug revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Long-Acting Schizophrenia Drug revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Johnson & Johnson
Teva
Eli Lilly
Bristol Myers Squibb
AstraZeneca
Sumitomo Dainippon Pharma
Allergan
Novartis
Cardinal Health
Sun Pharmaceutical Industries
GlaxoSmithKline
Sanis Health
Qilu Pharmaceutical
Otsuka Pharmaceutical
Vanda Pharmaceuticals
H.Lundbeck
Organon
Hansoh
Hengrui
Nhwa Group
Yangtze River Pharmaceutical Group
